However, to the best of our knowledge, information regarding the drug interactions of amifampridine mediated by NAT2 has not yet been reported, which possibly limits the effective treatment of LEMS with amifampridine. This evidence concerns the gene NAT2 and Lambert-Eaton myasthenic syndrome.